AVTX

MKT CAP:$859M

Avalo Therapeutics Inc

Market Cap

$859M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$13.10-$3.92 (-23.03%)

Jun 5, 2026

52W High $22.8752W Low $4.10

Company Details

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds...

CEO

—

IPO Date

Nov 13, 2015

Website

www.avalotx.com

Key Metrics TTM

Revenue

$59.0K

-86.6% YoY

Net Income

-$85M

EPS (Diluted)

Free Cash Flow

-$60M

Revenue / Share

$0.00

Gross Margin

-155.9%

Operating Margin

-134164.4%

Net Margin

-143627.1%

FCF Margin

-101172.9%

P/S

14566.9x

P/E

Earnings Reports

Q1 2026

May 13, 2026

FY 2025

Mar 23, 2026

$59.0K-86.6%

Q4 2025

Mar 23, 2026

$59.0K-69.3%

Q3 2025

Nov 6, 2025

$0-100.0%

Q2 2025

Aug 7, 2025

Revenue & Profitability

Valuation

Operating Cash Flow

CapEx Spend

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

War Chest

Shares Outstanding

Revenue Per Employee

Revenue / Employee